From 2000 to 2015, there were 13 clinical trials with 148 patients receiving DC immunotherapy for ovarian cancer targeting antigens that included MUC1, MUC16, HER2, and FOLR1, with variable and inconsistently reported results [4]. Here, FOLR1 is linked to ovarian carcinoma.